Skip to content

Women's Hormonal and Metabolic Wellbeing Study

A 12-Week Virtual, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effects of Daily Nouri Hormone Balance Probiotic on Metabolic, Inflammatory, and Symptom Outcomes in Women

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07268404
Enrollment
60
Registered
2025-12-05
Start date
2025-12-31
Completion date
2026-12-31
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Health

Keywords

dietary supplement, quality of life, women's health, hormone balance

Brief summary

The goal of this clinical trial is to learn if Daily Nouri Hormone Balance Probiotic blend can improve metabolic, inflammatory, and symptom outcomes in women. Participants will: * Take the probiotic blend or placebo every day for 12 weeks * Complete virtual assessments and report symptoms throughout the study

Detailed description

This study is a 12-week, prospective, randomized, controlled clinical trial. It is an interventional study with participants assigned to either an active or control group. All study visits will be conducted virtually, including completion of questionnaires, collection of blood samples, and other assessments.

Interventions

DIETARY_SUPPLEMENTProbiotic Blend Capsule

Hormone Balance Probiotic Blend

DIETARY_SUPPLEMENTPlacebo

Placebo

Sponsors

Daily Nouri
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Self-reported irregular menstrual cycles, defined as one or more of the following: * Cycle length typically \>35 days OR \<21 days * Fewer than 9 menstrual periods in the past year * Unpredictable cycle timing (varies by \>7 days month-to-month) * Irregular cycles present for ≥6 months * One or more of the following hormonal balance concerns: skin, unwanted hair growth, hair thinning, weight concerns) * Self-reported emotional symptoms that fluctuate with menstrual cycle, including: * Mood swings or irritability * Feelings of stress or tension * Low mood or feeling down * Difficulty with emotional regulation * Not currently using hormonal therapies, metformin, GLP-1 receptor agonists, or anti-androgens. * If taking supplements for menstrual/hormonal support: willing to discontinue for 2-week washout before baseline * Weight stable (+ 5 pounds) for the past 2 months, not planning to start a new diet, exercise program, or medications during study * Able to provide electronic informed consent. * Willing to complete online surveys and at-home DBS sample collection. * Negative home pregnancy test at baseline. * Access to a computer or smartphone and reliable internet connection.

Design outcomes

Primary

MeasureTime frameDescription
Women's Health Quality of Life ScoresFrom baseline to week 12Women's Health Quality of Life as measured by changes in total and domains scores on the Health-Related Quality of Life Questionnaire for Polycystic Ovary Syndrome-26 (PCOSQ-26). Response Scale: 7-Point Likert Scale Per-Item Range: minimum: 1, maximum: 7, where higher scores indicate better outcomes.

Secondary

MeasureTime frameDescription
Change from baseline to Week 12 in Fasting Blood Glucose12 weeksFasting Blood Glucose will be analyzed from dried blood spots (DBS), reported as mg/dL (milligrams per deciliter).
Change from baseline to Week 12 in Glycated Hemoglobin A1c (HbA1c)12 weeksHbA1c will be analyzed from dried blood spots (DBS), reported as percentage (%).
Change from baseline to Week 12 in High-Sensitivity C-Reactive Protein (hsCRP).12 weekshsCRP will be analyzed from dried blood spots (DBS), reported as mg/L (milligrams per liter).
Overall Health Quality of Life Scores12 weeksAssessed by monthly Patient-Reported Outcomes Measurement Information System - 29 Profile (PROMIS-29) questionnaire. 28 items use 5-point Likert scale responses (0-4), 1 item is a numeric rating scale (0-10). For negatively-worded concepts higher scores indicate worse outcomes, for positively-worded concepts higher scores indicate better outcomes.
Supplementary Question - Acne Severity12 weeksHow would you rate the severity of your acne over the past 7 days? Visual Analog Scale, (Response: 0-10 scale, where 0 = no acne and 10 = severe acne)
Supplementary Question - Acne12 weeksTo what extent does your acne currently affect your quality of life? (Response: 5-point Likert, from 'not at all' to 'extremely')
Supplementary Question - Sexual Health12 weeksOver the past 7 days, how would you rate your overall sexual interest and satisfaction? Visual Analog Scale (0 = Very poor, 10 = Excellent)
Supplementary Question - Sleep12 weeksOver the past 7 days, how would you rate your sleep quality overall? Visual Analog Scale, (0 = very poor, 10 = excellent) Over the past 7 days, how would you rate your energy level? Visual Analog Scale (0 = no energy/extremely fatigued, 10 = full energy/not fatigued at all)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026